|
Fulcrum Therapeutics ، Inc. (FULC) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Fulcrum Therapeutics, Inc. (FULC) Bundle
تبحث لتقييم القيمة الجوهرية لـ Fulcrum Therapeutics ، Inc.؟ يدمج حاسبة DCF (FULC) DCF بيانات العالم الحقيقي مع ميزات تخصيص شاملة ، مما يتيح لك ضبط التوقعات وتعزيز استراتيجيات الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 8.8 | 19.2 | 6.3 | 2.8 | 2.6 | 2.5 | 2.4 | 2.2 | 2.1 |
| Revenue Growth, % | 0 | 0 | 117.19 | -66.9 | -55.77 | -5.67 | -5.67 | -5.67 | -5.67 | -5.67 |
| EBITDA | -82.2 | -69.2 | -78.5 | -109.7 | -108.5 | -1.6 | -1.5 | -1.4 | -1.3 | -1.3 |
| EBITDA, % | 100 | -784.68 | -409.85 | -1730.05 | -3867.81 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 2.1 | 2.4 | 2.5 | 2.4 | 2.2 | 1.4 | 1.3 | 1.2 | 1.1 | 1.1 |
| Depreciation, % | 100 | 26.96 | 13.12 | 38.06 | 77.43 | 51.12 | 51.12 | 51.12 | 51.12 | 51.12 |
| EBIT | -84.2 | -71.6 | -81.1 | -112.1 | -110.7 | -1.6 | -1.5 | -1.4 | -1.3 | -1.3 |
| EBIT, % | 100 | -811.64 | -422.97 | -1768.12 | -3945.24 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 96.7 | 112.9 | 218.2 | 202.9 | 236.2 | 2.6 | 2.5 | 2.4 | 2.2 | 2.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .1 | 2.7 | 4.1 | 1.1 | 2.2 | 1.3 | 1.2 | 1.2 | 1.1 | 1.0 |
| Account Receivables, % | 100 | 30.68 | 21.45 | 17.05 | 80.18 | 49.87 | 49.87 | 49.87 | 49.87 | 49.87 |
| Inventories | 3.0 | -2.8 | -.5 | -.9 | .0 | .3 | .3 | .2 | .2 | .2 |
| Inventories, % | 100 | -31.52 | -2.47 | -13.43 | 0 | 10.52 | 10.52 | 10.52 | 10.52 | 10.52 |
| Accounts Payable | 2.2 | 4.1 | 4.8 | 3.6 | 2.8 | 1.7 | 1.6 | 1.5 | 1.5 | 1.4 |
| Accounts Payable, % | 100 | 46.23 | 24.99 | 57.36 | 98.29 | 65.37 | 65.37 | 65.37 | 65.37 | 65.37 |
| Capital Expenditure | -.9 | -1.3 | -1.7 | -2.0 | -.5 | -.4 | -.4 | -.3 | -.3 | -.3 |
| Capital Expenditure, % | 100 | -15.21 | -8.94 | -30.95 | -18.11 | -14.64 | -14.64 | -14.64 | -14.64 | -14.64 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -80.6 | -69.2 | -78.5 | -107.8 | -110.7 | -1.5 | -1.5 | -1.4 | -1.3 | -1.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -80.3 | -63.1 | -80.7 | -105.1 | -111.9 | -1.0 | -.6 | -.5 | -.5 | -.5 |
| WACC, % | 13.15 | 13.15 | 13.15 | 13.15 | 13.16 | 13.15 | 13.15 | 13.15 | 13.15 | 13.15 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -2.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -4 | |||||||||
| Present Terminal Value | -2 | |||||||||
| Enterprise Value | -4 | |||||||||
| Net Debt | -15 | |||||||||
| Equity Value | 10 | |||||||||
| Diluted Shares Outstanding, MM | 61 | |||||||||
| Equity Value Per Share | 0.17 |
What You Will Get
- Real FULC Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures to fit your analysis.
- Instant Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Fulcrum Therapeutics' future performance.
- User-Friendly Interface: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive FULC Data: Pre-loaded with Fulcrum Therapeutics’ historical financials and future projections.
- Customizable Input Parameters: Modify revenue growth rates, margins, WACC, tax rates, and capital expenditures to suit your analysis.
- Interactive Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your adjustments.
- Multiple Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
- Intuitive User Interface: Designed for ease of use, catering to both professionals and novices.
How It Works
- Step 1: Download the prebuilt Excel template featuring Fulcrum Therapeutics, Inc. (FULC) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Adjust forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see recalculated results, including Fulcrum Therapeutics, Inc. (FULC) intrinsic value.
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose Fulcrum Therapeutics, Inc. (FULC)?
- Innovative Solutions: Focuses on developing transformative therapies for rare genetic diseases.
- Expert Team: Comprised of industry leaders and experienced professionals dedicated to advancing drug development.
- Robust Pipeline: Features a diverse range of drug candidates in various stages of clinical trials.
- Strong Partnerships: Collaborates with leading institutions and organizations to enhance research and development efforts.
- Commitment to Patients: Prioritizes patient needs and strives to improve quality of life through innovative treatments.
Who Should Use This Product?
- Pharmaceutical Students: Understand drug development processes and apply them to real-world scenarios.
- Researchers: Integrate advanced models into studies or academic projects related to therapeutics.
- Investors: Evaluate your own strategies and assess the market potential for Fulcrum Therapeutics, Inc. (FULC).
- Healthcare Analysts: Enhance your analysis with a customizable financial model specific to biotech companies.
- Entrepreneurs: Discover how large biotech firms like Fulcrum Therapeutics, Inc. (FULC) navigate the market landscape.
What the Template Contains
- Pre-Filled DCF Model: Fulcrum Therapeutics' financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Fulcrum Therapeutics' profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.